The purpose of this study is to gather data regarding the utilization of the FARAVIEW™ feature of the RHYTHMIA HDx Mapping System when used in conjunction with the FARAWAVE NAV Pulsed Field Ablation catheter in subjects undergoing catheter-based endocardial mapping and catheter-based ablation treatment of Atrial Fibrillation.

The objective of this study is to obtain First-in-Human (FIH) experience with the FARAVIEW™ technology of the RHYTHMIA HDx™ Mapping System when it is used to visualize and track the FARAWAVE NAV™ Pulsed Field Ablation (PFA) catheter in the treatment of Atrial Fibrillation (AF). The study will collect FIH data on user experience and workflow using the FARAVIEW technology to visualize and track the FARAWAVE NAV PFA catheter (part of the FARAPULSE™ Pulsed Field Ablation System). Subjects with Paroxysmal and Persistent Atrial Fibrillation will be included in this study.

NAVIGATE PF Phase 2 has the same objective of the NAVIGATE PF study and incorporates a Day 60 remapping procedure and Day 90 safety follow-up. This procedure has the additional objective to assess durability of isolation and to compare electro-anatomical maps information between Index procedure and Day 60 remapping. One clinical site in Europe that participated in NAVIGATE PF and enrolled under protocol ver A., will contribute enrollments in Phase 2 of the NAVIGATE PF study. Approximately 30 subjects will be enrolled in Phase 2 of the NAVIGATE PF study.

Inclusion Criteria:

1. Age: ≥ 18 years of age, or older if required by local law

2. Symptomatic, documented, drug-resistant, Atrial Fibrillation

   1. Documented: at a minimum a physician's note confirming the arrhythmia symptoms and durations AND within 180 days of the Enrollment Date one (1) ECG from any regulatory cleared rhythm monitoring device showing AF
   2. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one (1) AAD (Class I, II, III or IV) 1

3. Informed consent: willing and capable of providing informed consent

4. Full participation: willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center

Exclusion Criteria:

1. Atrial exclusions - Any of the following atrial conditions:

   1. Prior atrial ablation: any prior atrial endocardial, epicardial or surgical ablation procedure for arrhythmia other than ablation for right sided SVT or cavotricuspid isthmus ablation
   2. Atrial myxoma: current atrial myxoma
   3. Pulmonary veins: any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
   4. Atrial thrombus: current left atrial thrombus
   5. Long standing persistent AF: continuous AF lasting longer than 12 months

2. Cardiovascular exclusions - Any of the following CV conditions:

   1. Ventricular arrhythmia: history of sustained ventricular tachycardia or any ventricular fibrillation
   2. Secondary AF: AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
   3. Cardiac devices and implants: current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, interatrial baffle, closure device, patch, or patent foramen ovale or ASD occluder, LA appendage closure, device or occlusion.
   4. Clinically significant valvular disease: valvular disease that is any of the following:

   i. Symptomatic ii. Causing or exacerbating congestive heart failure iii. Associated with abnormal LV function or hemodynamic measurements e. Cardiomyopathy i. Hypertrophic cardiomyopathy ii. Cardiac amyloidosis f. Valve prostheses: any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty g. Access issues: any IVC filter, known inability to obtain vascular access or other contraindication to femoral access h. Rheumatic disease: rheumatic heart disease i. Anticipated cardiac surgery: awaiting cardiac transplantation or other cardiac surgery within the next 12 months

3. Any of the following conditions at baseline (Section 10.4):

   1. Heart failure NYHA Heart failure associated with NYHA IV
   2. Ejection fraction: LVEF < 40%

4. Any of the following events within 90 Days of the Consent Date:

   1. Coronary disease: myocardial infarction (MI), unstable or coronary intervention
   2. Cardiac surgery: any cardiac surgery
   3. Heart failure hospitalization: heart failure hospitalization
   4. Pericardium: pericarditis or symptomatic pericardial effusion
   5. GI bleeding: gastrointestinal bleeding
   6. Neurovascular event: stroke, TIA, or intracranial bleeding
   7. Thromboembolism: any non-neurologic thromboembolic event
   8. Carotid intervention: carotid stenting or endarterectomy

5. Bleeding diathesis: thrombocytosis, thrombocytopenia, disorder of blood clotting or bleeding diathesis

6. Contraindication to anticoagulation: contraindication to, or unwillingness to use, systemic anticoagulation

7. Pregnancy: women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period

8. Health conditions that in the investigator's medical opinion would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to:

   1. Obesity: Body Mass Index (BMI) > 45.0
   2. Transplantation: solid organ or hematologic transplant, or currently being evaluated for a transplant
   3. Diaphragmatic abnormality: any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
   4. Pulmonary: severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
   5. Renal: renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL / min / 1.73 m2, or with any history of renal dialysis or renal transplant
   6. Malignancy: active malignancy (other than cutaneous basal cell or squamous cell carcinoma)
   7. Gastrointestinal: clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
   8. Infections: active systemic infection
   9. COVID-19 disease: known positive test for COVID-19 and disease not clinically resolved

9. Life expectancy: predicted life expectancy less than one (1) year

10. Participation in another trial: subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility

11. Congenital heart disease: congenital heart disease with any clinically significant residual anatomic or conduction abnormality